RFRawan M. Fayyad

Rawan M. Fayyad

*This is an algorithmically generated author record based on publicly available information.

Rawan M. Fayyad has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A synthetic, small-molecule, allosteric inhibitor of human factor XIa for thrombosis

    by Chiranjeev Sharma, Rama Gunta, Sridhar R. Iyer, Rawan M. Fayyad, Elsamani I. Abdelfadiel, Andrew Hadsdy, Erika J. Martin, Priyanka Mishra, Bharath Kumar Villuri, Nilesh Pandey, et al.

    Only a handful of anticoagulants have reached the clinic to treat and prevent thrombotic episodes in the millions of patients with cardiovascular, cancer, viral (COVID-19), and metabolic diseases. In this study, we report the discovery, chemical synthesis, mechanistic biochemistry, pharmacology, and toxicology of SB-01, a novel, allosteric, activated human factor XIa (hFXIa) inhibitor that displays potent antithrombotic activity in preclinical models. SB-01 is a synthetic, highly sulfated, aromatic agent that binds in both anion-binding exosites of hFXIa to induce inhibition of FIX activation. SB-01 inhibited rodent arterial and venous thrombosis at doses of 6 and 3 mg/kg, respectively. In addition, a twice-a-day regimen of 6 mg/kg SB-01 was significantly more effective (P< .001) in preventing deep vein thrombosis in animals with lung cancer. Michaelis-Menten kinetics and competition with unfractionated heparin and polyphosphate revealed SB-01 to be an allosteric inhibitor. Critically, at the effective dose of 6 mg/kg, SB-01 did not significantly increase mouse tail bleeding time or blood loss. Furthermore, SB-01’s anticoagulation could be readily reversed with protamine sulfate, the US Food and Drug Administration–approved antidote for heparin. Finally, SB-01 showed no major adverse effects across multiple toxicological assays including gross, cardiac, metabolic, hematological, and clinical chemistry. Overall, this study presents a structurally and functionally unique, allosteric small molecule as a highly promising candidate for safer anticoagulation.